AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO)

Historical Holders from Q1 2014 to Q3 2025

Symbol
AGIO on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
58.6M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
63.5M
Holdings value
$2.55B
% of all portfolios
0.005%
Grand Portfolio weight change
+0%
Number of holders
215
Number of buys
105
Number of sells
-103
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 9.9% $166M 5.67M Dapice Joshua J. 31 Dec 2024
BlackRock, Inc. 7.8% $150M 4.51M BlackRock, Inc. 30 Jun 2025
Paradigm Biocapital Advisors LP 4.9% -6% $115M -$6.2M 2.87M -5.1% Paradigm BioCapital Advisors LP 30 Sep 2025

Institutional Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 63.5M $2.55B +$81.8M $40.14 215
2025 Q2 61.7M $2.05B +$65.2M $33.26 211
2025 Q1 60M $1.76B -$10.2M $29.30 216
2024 Q4 59.8M $1.97B +$38M $32.86 221
2024 Q3 58.1M $2.58B -$8.18M $44.43 204
2024 Q2 58.1M $2.51B -$125M $43.12 203
2024 Q1 61.9M $1.81B +$89.2M $29.24 183
2023 Q4 59.9M $1.33B +$15.9M $22.27 167
2023 Q3 59.1M $1.46B -$8.92M $24.75 142
2023 Q2 59.4M $1.68B +$16.4M $28.32 150
2023 Q1 59M $1.36B -$9.99M $22.97 161
2022 Q4 59.4M $1.67B +$45.1M $28.08 156
2022 Q3 58M $1.64B -$46.4M $28.28 155
2022 Q2 59M $1.31B -$21.4M $22.17 143
2022 Q1 59.9M $1.74B +$19.2M $29.11 146
2021 Q4 59.2M $1.95B -$73.8M $32.87 148
2021 Q3 60.9M $2.81B -$244M $46.15 157
2021 Q2 65.9M $3.63B +$51.4M $55.11 179
2021 Q1 65.2M $3.37B +$56.1M $51.64 168
2020 Q4 65M $2.82B -$19.4M $43.33 189
2020 Q3 65.9M $2.3B -$102M $35.00 206
2020 Q2 67.5M $3.61B -$76.3M $53.48 205
2020 Q1 69.4M $2.46B +$6.22M $35.48 188
2019 Q4 69M $3.3B +$348M $47.75 192
2019 Q3 61.9M $2.01B +$38.1M $32.40 180
2019 Q2 60.7M $3.03B +$158M $49.88 182
2019 Q1 60.1M $4.06B +$163M $67.44 191
2018 Q4 58M $2.67B +$50M $46.11 182
2018 Q3 55.6M $4.29B +$92.8M $77.12 199
2018 Q2 54.4M $4.58B -$33.6M $84.23 207
2018 Q1 54.8M $4.48B +$717M $81.78 192
2017 Q4 47M $2.69B +$50.5M $57.17 173
2017 Q3 46.1M $3.07B +$18M $66.75 168
2017 Q2 46.1M $2.37B +$326M $51.45 164
2017 Q1 41M $2.39B +$241M $58.40 154
2016 Q4 39M $1.63B +$42.9M $41.73 154
2016 Q3 37.8M $2B +$256M $52.82 160
2016 Q2 34M $1.42B +$19.3M $41.89 150
2016 Q1 33.8M $1.37B +$17.9M $40.60 151
2015 Q4 33M $2.14B +$96.2M $64.92 141
2015 Q3 31.4M $2.22B +$82.8M $70.59 149
2015 Q2 30.1M $3.35B +$244M $111.14 159
2015 Q1 28M $2.64B -$37M $94.30 149
2014 Q4 27.7M $3.1B +$395M $112.04 142
2014 Q3 24.5M $1.5B +$81.5M $61.35 119
2014 Q2 23.6M $1.08B +$140M $45.82 99
2014 Q1 20.5M $804M +$93.8M $39.15 73